60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

• Hannes Loferer,
• Stefan Bissinger,
• Ilona-Petra Maser,
• Sonja Lacher,
• Marisa Stebegg,
• Vincent Piras,
• Barbara Kracher,
• Kai Quirin,
• Murray Yule

Affiliations

Hannes Loferer

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Stefan Bissinger

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Ilona-Petra Maser

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Sonja Lacher

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Marisa Stebegg

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Vincent Piras

2Evotec SAS, Toulouse, France

Barbara Kracher

3Evotec GmbH, Neuried/Munich, Germany

Kai Quirin

1iOmx Therapeutics AG, Martinsried/Munich, Germany

Murray Yule

1iOmx Therapeutics AG, Martinsried/Munich, Germany